Composition and method for treatment of CMV retinites

• US 5,595,978 A
• Filed: 04/26/1994
• Issued: 01/21/1997
• Est. Priority Date: 08/16/1990
• Status: Expired due to Term

• Current Assignee: ISIS Pharmaceuticals Incorporated (Ionis Pharmaceuticals, Inc.)
• Original Assignee: ISIS Pharmaceuticals Incorporated (Ionis Pharmaceuticals, Inc.)
• Inventors: Draper, Kenneth G., Kisner, Daniel L., Chapman, Sharon K.
• Primary Examiner(s): Leguyader, John L.
• Application Number:
  US08/233,711
• Time in Patent Office: 1,001 Days
• Field of Search: 435/91.1, 435/6, 514/44, 536/23.1, 536/24.5
• US Class Current: 514/44.00A
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: C12N 15/1133 against herpetoviridae, e.g. HSV
• CPC Class Codes: C12N 2310/315 Phosphorothioates
• CPC Class Codes: C12N 2310/321 2'-O-R Modification
• CPC Class Codes: C12N 2310/322 2'-R Modification
• CPC Class Codes: C12N 2310/3521 Methyl
• CPC Class Codes: C12N 2310/3527 Other alkyl chain

Abstract

This invention concerns compositions and methods for the treatment of CMV infections. A composition including an antisense oligonucleotide targeted to the IE2 gene of CMV and a pharmaceutically acceptable carrier were used stop progression in CMV retinitis.

Claims

1. A method for treating CMV retinitis comprising administering by intravitreal injection an effective amount of a composition comprising SEQ ID NO:

1 and a pharmaceutically acceptable carrier to an animal having CMV retinitis.

2. The method of claim 1 wherein the pharmaceutically acceptable carrier is a buffered solution.

3. The method of claim 1 wherein the animal is a human.

4. A composition comprising SEQ ID NO:

1 and a pharmaceutically acceptable carrier.

6. A method for the treatment of CMV retinitis comprising administering an effective amount of a composition of claim 4 intravitreally in combination with ganciclovir to an animal having CMV retinitis.

8. A method for the treatment of CMV retinitis comprising administering an effective amount of a composition of claim 4 intravitreally in combination with foscarnet to an animal having CMV retinitis.

5. A composition comprising SEQ ID NO:

1 and a bicarbonate buffered solution.

7. A method for the treatment of CMV retinitis comprising administering an effective amount of a composition of claim 5 intravitreally in combination with ganciclovir to an animal having CMV retinitis.

9. A method for the treatment of CMV retinitis comprising administering an effective amount of a composition of claim 5 intravitreally in combination with foscarnet to an animal having CMV retinitis.